Glimibose-M2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The combination of these two agents provides complementary mechanisms of action to achieve better glycemic control than monotherapy. Glimibose-M2 Tablet PR is indicated for adult patients inadequately controlled on diet and exercise alone or those who require dual therapy to optimize glycemic control. It is particularly beneficial for patients with insulin resistance and impaired pancreatic function. The prolonged-release formulation ensures a steady plasma concentration, improving patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Dosage should be individualized based on patient response and tolerability, with regular monitoring of blood glucose levels and renal function recommended. Contraindications include severe renal impairment, diabetic ketoacidosis, and hypersensitivity to any component. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare allergic reactions. Proper lifestyle modifications should accompany pharmacotherapy for optimal outcomes.